ZA200709091B - Erythropoietin variants - Google Patents

Erythropoietin variants

Info

Publication number
ZA200709091B
ZA200709091B ZA200709091A ZA200709091A ZA200709091B ZA 200709091 B ZA200709091 B ZA 200709091B ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 B ZA200709091 B ZA 200709091B
Authority
ZA
South Africa
Prior art keywords
erythropoietin variants
erythropoietin
variants
Prior art date
Application number
ZA200709091A
Other languages
English (en)
Inventor
Meisel Andreas
Priller Josef
Bonnas Christel
Dirnagl Ulrich
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Publication of ZA200709091B publication Critical patent/ZA200709091B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200709091A 2005-05-13 2007-10-22 Erythropoietin variants ZA200709091B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants

Publications (1)

Publication Number Publication Date
ZA200709091B true ZA200709091B (en) 2009-08-26

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709091A ZA200709091B (en) 2005-05-13 2007-10-22 Erythropoietin variants

Country Status (12)

Country Link
EP (2) EP1736481A1 (OSRAM)
JP (1) JP5231214B2 (OSRAM)
KR (1) KR101468737B1 (OSRAM)
CN (1) CN101175768B (OSRAM)
AU (1) AU2006245916B2 (OSRAM)
BR (1) BRPI0608769A2 (OSRAM)
CA (1) CA2608379C (OSRAM)
DK (1) DK1885747T3 (OSRAM)
ES (1) ES2457398T3 (OSRAM)
RU (1) RU2430162C2 (OSRAM)
WO (1) WO2006120030A1 (OSRAM)
ZA (1) ZA200709091B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339613B (es) 2005-08-05 2016-06-02 Araim Pharmaceuticals Inc Peptidos protectores de tejido y sus usos.
WO2008137636A2 (en) * 2007-05-02 2008-11-13 University Of Utah Research Foundation Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
NZ601868A (en) 2008-01-22 2014-05-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
KR102233664B1 (ko) 2012-12-05 2021-04-02 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
EP3456817B1 (en) 2013-02-06 2025-07-09 Nc Medical Research Inc. Heterogeneous subpopulation of bone marrow cells for use in the treatment of neurodegeneration caused by ischemic stroke
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US11117942B2 (en) 2015-08-31 2021-09-14 The Trustees Of The University Of Pennsylvania AAV-EPO for treating companion animals
EP3587443A4 (en) * 2017-02-27 2021-02-17 Sylus Co., Ltd. USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
EP3916008A1 (en) * 2020-05-26 2021-12-01 Sylus Co., Ltd. New peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
EP4355425A1 (en) * 2021-06-15 2024-04-24 Andremacon S.r.l. Epo variants and modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
GB2413328A (en) * 2004-04-23 2005-10-26 Cambridge Antibody Tech Erythropoietin protein variants

Also Published As

Publication number Publication date
KR20080021595A (ko) 2008-03-07
RU2430162C2 (ru) 2011-09-27
CA2608379A1 (en) 2006-11-16
AU2006245916A1 (en) 2006-11-16
JP2008539745A (ja) 2008-11-20
EP1736481A1 (en) 2006-12-27
EP1885747B1 (en) 2013-11-20
JP5231214B2 (ja) 2013-07-10
EP1885747A1 (en) 2008-02-13
BRPI0608769A2 (pt) 2010-01-26
AU2006245916B2 (en) 2012-03-15
CA2608379C (en) 2014-12-16
RU2007146455A (ru) 2009-06-20
CN101175768A (zh) 2008-05-07
DK1885747T3 (en) 2014-02-24
KR101468737B1 (ko) 2014-12-09
CN101175768B (zh) 2013-09-11
WO2006120030A8 (en) 2006-12-28
ES2457398T3 (es) 2014-04-25
WO2006120030A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ZA200709091B (en) Erythropoietin variants
IL232923A0 (en) Enhanced erythropoietin
GB0513284D0 (en) I-kinisis
DE602006014261D1 (en) Benzimidazolverbindungen
DE602006009835D1 (en) Nthalten
EP1934350A4 (en) POLYOLEOSINE
DE602006021558D1 (en) Modulare montgomery-multiplikationseinrichtung
EP1865780A4 (en) MINI OVEN
GB0514300D0 (en) Imflammation
DE502006004337D1 (en) Strangführungsrolle
GB0512706D0 (en) Cutter-grinder
GB0512249D0 (en) Hayfit3
GB0504960D0 (en) Benzoxazocines
GB0509722D0 (en) Pieangle
GB0503679D0 (en) Gumbuddy
GB0505768D0 (en) Spare-AD2
AU4036P (en) Dottie Calathea roseo-picta
AU3685P (en) DOW10 Tristaniopsis laurina
GB0516150D0 (en) Improved smpsogi
GR1007111B (en) Assembled ballot-box
GB0511729D0 (en) Vibropager
GB0511007D0 (en) Sensigum
GB0500322D0 (en) Slide-in-plate
GB0505469D0 (en) Super-powered car-jack
AU305161S (en) Ballpen